Here is how Stryker (SYK) and BrightSpring Health Services, Inc. (BTSG) have performed compared to their sector so far this year.

Stryker Corp (SYK) reports robust sales and EPS growth, raises full-year guidance despite ongoing supply chain issues.

Medical technology company Stryker (NYSE:SYK) reported Q2 CY2025 results , with sales up 11.1% year on year to $6.02 billion.

Medical technology company Stryker (NYSE:SYK) will be reporting results this Thursday after market close. Here’s what you ...

Revenue (GAAP) increased 11.1% to $6.0 billion, above analyst expectations. Adjusted earnings per share rose 11.4% to $3.13, exceeding consensus estimates. Full-year 2025 guidance was raised for both ...

Insights from analysts' 12-month price targets are revealed, presenting an average target of $429.5, a high estimate of $455.00, and a low estimate of $400.00. Marking an increase of 3.18%, the ...

Stryker will increase its full-year guidance after a Street-beating second quarter that saw strong demand for products and continued business momentum.

Written by Zacks Equity Research for Zacks -> A month has gone by since the last earnings report for Stryker (SYK). Shares have added about 8.8% in that time frame, outperforming the S&P 500.

Stryker Corporation’s (NYSE:SYK) revenue increased 10.1% organically in fiscal Q1 2025, exceeding expectations by 3%. The growth was consistent across various segments and regions, pointing to a ...

Fintel reports that on September 10, 2024, Wolfe Research initiated coverage of Stryker (NYSE:SYK) with a Outperform recommendation. Analyst Price Forecast Suggests 6.51% Upside As of August 26 ...

Stifel Nicolaus analyst Rick Wise maintained a Buy rating on Stryker (SYK – Research Report) today and set a price target of $365.00. The company’s shares closed yesterday at $330.22.

Stryker Corporation (SYK)’s share was trading at $360.98 as of Jan 13 th. SYK’s trailing and forward P/E were 38.69 and 26.74 respectively according to Yahoo Finance.